Final Analysis Of The Efficacy and Tolerability Of Subcutaneous Omacetaxine Mepesuccinate, ≥24 Months After First Dose, In Patients With Chronic Phase (CP) Or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML)
暂无分享,去创建一个
M. Baccarani | J. Cortes | C. Chuah | J. Lipton | H. Khoury | M. Wetzler | F. Nicolini | R. Digumarti | P. Parikh | P. Brown | M. Michallet | M. Munteanu | D. Réa | E. Li | P. Kropf